This site is intended for US healthcare professionals.
Evolving rrRCC Management
The Management of rrRCC
Is Rapidly Evolving
There is a lack of phase 3 data beyond second line
Making clinical decisions is challenging in this rapidly changing field12
As a result of recent improvements in overall survival, there is a growing population of patients with highly refractory disease who have received prior checkpoint inhibitors and need new later-line treatment options13,14
Later-Line RCC Therapy Has Proven Benefits
Post−second-line treatment can offer meaningful efficacy
A retrospective analysis of treatment of 4824 International Metastatic Renal Cell Carcinoma Database Consortium patients found that mRCC patients who received third-line therapy had an increased median survival approximately twice that of those who did not receive treatment (14.9 vs 7.6 months, respectively).2
“The tolerability [of regimens] is an issue when considering third- and fourth-line therapies. By the fourth line, most patients are just beaten up by treatment, so you can only really discuss hospice care.”
Reprinted from European Urology, 71(2), Wells JC, Stukalin I, Norton C, et al. Third-line targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium, 204-220, 2017, with permission from Elsevier.
Kaplan-Meier curve showing OS from time of cessation of second-line therapy for patients receiving third-line therapy (n=715) or not (n=345), excluding patients who died within 3 months of cessation.